Cargando…
Theaflavin 3-gallate inhibits the main protease (M(pro)) of SARS-CoV-2 and reduces its count in vitro
The main protease (M(pro)) of SARS-CoV-2 has been recognized as an attractive drug target because of its central role in viral replication. Our previous preliminary molecular docking studies showed that theaflavin 3-gallate (a natural bioactive molecule derived from theaflavin and found in high abun...
Autores principales: | Chauhan, Mahima, Bhardwaj, Vijay Kumar, Kumar, Asheesh, Kumar, Vinod, Kumar, Pawan, Enayathullah, M. Ghalib, Thomas, Jessie, George, Joel, Kumar, Bokara Kiran, Purohit, Rituraj, Kumar, Arun, Kumar, Sanjay |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338964/ https://www.ncbi.nlm.nih.gov/pubmed/35908093 http://dx.doi.org/10.1038/s41598-022-17558-5 |
Ejemplares similares
-
A ricin-based peptide BRIP from Hordeum vulgare inhibits M(pro) of SARS-CoV-2
por: Kashyap, Prakriti, et al.
Publicado: (2022) -
Antimicrobial silver nanoparticle-photodeposited fabrics for SARS-CoV-2 destruction
por: Kumar, Aditya, et al.
Publicado: (2021) -
Evaluation of acridinedione analogs as potential SARS-CoV-2 main protease inhibitors and their comparison with repurposed anti-viral drugs
por: Bhardwaj, Vijay Kumar, et al.
Publicado: (2021) -
Benchmarking the ability of novel compounds to inhibit SARS-CoV-2 main protease using steered molecular dynamics simulations
por: Singh, Rahul, et al.
Publicado: (2022) -
Gramicidin S and melittin: potential anti-viral therapeutic peptides to treat SARS-CoV-2 infection
por: Enayathullah, Mohammed Ghalib, et al.
Publicado: (2022)